Solid Biosciences Inc - רווח למניה בשנים עשר החודשים האחרונים SLDB

This daily EPS (TTM) chart for Solid Biosciences Inc. (SLDB) reflects a value of 28.90. This trend is driven by the development of treatments for rare muscle and nerve pathologies, with profits expected following the certification of new drugs. While development is conducted in-house, component production is outsourced to third-party contractors. High R&D costs and stringent FDA oversight create significant barriers to entry.

Solid Biosciences Inc. (SLDB) focuses on developing innovative gene therapy methods for Duchenne muscular dystrophy. The annual percentage change in earnings per share (TTM) reflects the growth rate of net income over the last twelve months relative to the previous year. This indicator measures the efficiency of monetizing developments and the company's ability to generate profit per share of capital. A positive trend confirms the commercial success of the SGT-003 platform and the long-term investment attractiveness of the asset.